Olin Corp (OLN) investors sentiment increased to 1.29 in 2017 Q4. It’s up 0.34, from 0.95 in 2017Q3. The ratio has improved, as 153 institutional investors opened new or increased stock positions, while 119 reduced and sold their positions in Olin Corp. The institutional investors in our database now possess: 144.77 million shares, down from 147.38 million shares in 2017Q3. Also, the number of institutional investors holding Olin Corp in top ten stock positions was flat from 3 to 3 for the same number . Sold All: 30 Reduced: 89 Increased: 97 New Position: 56.
Analysts expect Johnson & Johnson (NYSE:JNJ) to report $2.01 EPS on April, 17.They anticipate $0.18 EPS change or 9.84% from last quarter’s $1.83 EPS. JNJ’s profit would be $5.39 billion giving it 15.94 P/E if the $2.01 EPS is correct. After having $1.74 EPS previously, Johnson & Johnson’s analysts see 15.52% EPS growth. The stock increased 0.55% or $0.7 during the last trading session, reaching $128.15. About 6.12 million shares traded. Johnson & Johnson (NYSE:JNJ) has risen 1.12% since March 30, 2017 and is uptrending. It has underperformed by 10.43% the S&P500.
Investors sentiment increased to 0.87 in 2017 Q4. Its up 0.04, from 0.83 in 2017Q3. It improved, as 35 investors sold Johnson & Johnson shares while 884 reduced holdings. 143 funds opened positions while 654 raised stakes. 1.72 billion shares or 0.40% more from 1.71 billion shares in 2017Q3 were reported. Deprince Race Zollo invested 0.45% of its portfolio in Johnson & Johnson (NYSE:JNJ). Middleton And Ma accumulated 38,787 shares. Davenport Communication Ltd Liability Co invested in 2.34% or 1.40M shares. Norman Fields Gottscho Capital Management Limited Co has 6,495 shares. Centurylink Investment stated it has 40,134 shares or 1.98% of all its holdings. Weatherstone Mgmt reported 0.24% stake. Green Square Cap Ltd has invested 1.23% in Johnson & Johnson (NYSE:JNJ). Forward Management Limited Co owns 9,658 shares. Stifel Financial Corp has invested 0.93% of its portfolio in Johnson & Johnson (NYSE:JNJ). Spinnaker Trust reported 1.21% of its portfolio in Johnson & Johnson (NYSE:JNJ). Professional Advisory Inc reported 114,445 shares or 3.37% of all its holdings. Parkside Bank & Trust Tru invested 0.98% in Johnson & Johnson (NYSE:JNJ). 21,237 were reported by Community Fincl Svcs Group Inc Inc Ltd Com. Private Wealth Prtn Limited Liability Corp invested 0.81% in Johnson & Johnson (NYSE:JNJ). 14,202 were accumulated by Cedar Hill Assoc.
Since February 15, 2018, it had 0 buys, and 1 sale for $20.17 million activity. Stoffels Paulus sold $20.17M worth of Johnson & Johnson (NYSE:JNJ) on Thursday, February 15.
Johnson & Johnson, together with its subsidiaries, researches and develops, makes, and sells various products in the health care field worldwide. The company has market cap of $343.78 billion. It operates through three divisions: Consumer, Pharmaceutical, and Medical Devices. It has a 270.36 P/E ratio. The Consumer segment offers baby care products under the JOHNSONÂ’S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSONÂ’S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Among 23 analysts covering Johnson & Johnson (NYSE:JNJ), 11 have Buy rating, 5 Sell and 7 Hold. Therefore 48% are positive. Johnson & Johnson had 92 analyst reports since August 7, 2015 according to SRatingsIntel. The rating was downgraded by JP Morgan on Tuesday, January 2 to “Neutral”. The company was upgraded on Monday, October 9 by Wells Fargo. The firm has “Buy” rating given on Wednesday, October 18 by RBC Capital Markets. On Wednesday, October 18 the stock rating was maintained by Leerink Swann with “Buy”. The firm has “Outperform” rating by RBC Capital Markets given on Wednesday, October 7. The firm earned “Buy” rating on Tuesday, June 13 by Cowen & Co. The firm has “Underweight” rating given on Friday, July 21 by Alembic. Morgan Stanley maintained Johnson & Johnson (NYSE:JNJ) rating on Wednesday, October 18. Morgan Stanley has “Equal-Weight” rating and $145 target. Wells Fargo downgraded the stock to “Market Perform” rating in Thursday, January 26 report. Jefferies maintained Johnson & Johnson (NYSE:JNJ) on Friday, July 14 with “Hold” rating.
Ratings analysis reveals 50% of Olin’s analysts are positive. Out of 2 Wall Street analysts rating Olin, 1 give it “Buy”, 1 “Sell” rating, while 0 recommend “Hold”. The lowest target is $29.33 while the high is $37.0. The stock’s average target of $33.17 is 9.15% above today’s ($30.39) share price. OLN was included in 3 notes of analysts from September 7, 2016. On Friday, February 10 the stock rating was maintained by Cowen & Co with “Outperform”. On Wednesday, September 7 the stock rating was downgraded by Longbow to “Underperform”.
King Street Capital Management L.P. holds 8.36% of its portfolio in Olin Corporation for 3.00 million shares. Kensico Capital Management Corp owns 7.85 million shares or 5.56% of their US portfolio. Moreover, Iridian Asset Management Llc Ct has 2.32% invested in the company for 7.76 million shares. The Missouri-based Jag Capital Management Llc has invested 2.07% in the stock. Oarsman Capital Inc., a Wisconsin-based fund reported 124,018 shares.
Olin Corporation manufactures and distributes chemical products in the United States and internationally. The company has market cap of $5.08 billion. It operates through three divisions: Chlor Alkali Products and Vinyls; Epoxy; and Winchester. It has a 9.32 P/E ratio. The Chlor Alkali Products and Vinyls segment offers chlorine and caustic soda, ethylene dichloride and vinyl chloride monomers, methyl chloride, methylene chloride, chloroform, carbon tetrachloride, perchloroethylene, trichloroethylene and vinylidene chloride, hydrochloric acid, hydrogen, bleach products, and potassium hydroxide.
Analysts await Olin Corporation (NYSE:OLN) to report earnings on May, 1. They expect $0.22 EPS, up 57.14% or $0.08 from last year’s $0.14 per share. OLN’s profit will be $36.78M for 34.53 P/E if the $0.22 EPS becomes a reality. After $0.35 actual EPS reported by Olin Corporation for the previous quarter, Wall Street now forecasts -37.14% negative EPS growth.
Since January 1, 0001, it had 3 insider buys, and 2 selling transactions for $61,635 activity.
The stock increased 1.91% or $0.57 during the last trading session, reaching $30.39. About 1.22 million shares traded. Olin Corporation (OLN) has declined 8.60% since March 30, 2017 and is downtrending. It has underperformed by 20.15% the S&P500.
The post EPS for Johnson & Johnson (JNJ) Expected At $2.01; Olin (OLN) Has 1.29 Sentiment appeared first on Stock Market News | HillCountryTimes | Get it Today.
from
https://www.hillcountrytimes.com/2018/03/30/eps-for-johnson-johnson-jnj-expected-at-2-01-olin-oln-has-1-29-sentiment/
No comments:
Post a Comment